Mrs. Joan E Altman Neumann, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1436 Broadway, Hewlett, NY 11557 Phone: 516-563-7200 Fax: 516-563-7295 |
Mr. Victor A Rosenberg, MD Obstetrics & Gynecology - Maternal & Fetal Medicine Medicare: Medicare Enrolled Practice Location: 1229 Broadway, Suite 201, Hewlett, NY 11557 Phone: 516-501-9840 Fax: 516-501-9850 |
Dr. Rivkie Penstein-hirt, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1157 Broadway, Suite 3, Hewlett, NY 11557 Phone: 516-569-9100 Fax: 516-569-9200 |
Dr. Howard Shulman, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 178 Torquay Pl, Hewlett, NY 11557 Phone: 516-374-5022 Fax: 516-374-5023 |
Alex G Hirsch, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1800 Rockaway Ave, Suite 211, Hewlett, NY 11557 Phone: 516-593-7500 Fax: 516-593-7535 |
News Archive
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia.
Politico: Some House Democrats are touting the new health law — and their support of it — as a positive in their fights to keep their seats in midterm elections this fall. The Democrats are "framing key provisions as a 'Patient's Bill of Rights.' Spurred by last week's release of a series of rigid insurance rules, the lawmakers are defying this election season's conventional wisdom placing by health care front and center." Among them are Reps. Dina Titus and Shelley Berkley or Nevada.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
The majority of people - including healthcare professionals - are unable to visually identify whether a person is a healthy weight, overweight or obese according to research by psychologists at the University of Liverpool.
› Verified 3 days ago